Oesophageal doppler monitoring firm Deltex Medical Group on Wednesday appointed Andy Mears as chief executive after Ewan Phillips resigned as from the role.
Mears will take over the role with immediate effect after Phillips approached the AIM traded company's chairman with the assertion that there should be a change in leadership to guide the group through its next stage of development.

Nigel Keen, chairman of Deltex, said: "I want to thank Ewan Phillips for his work and dedication to Deltex over the last 17 years, the second half of these as chief executive. During this time the group has expanded significantly the evidence base which demonstrates the superior data generated for clinicians by Deltex's oesophageal doppler monitoring technology."

According to Deltex, Phillips felt that following a successful fundraising in February, recent cost reductions and the launch of the TrueVue platform, the company is now well-positioned for the future.

Currently the managing director of Deltex Medical Limited, Deltex Medical Group's principal operating subsidiary, Mears started at Deltex as an engineer in 1989 before working in a number of operational roles.

In his current role, he oversees international sales and the company's key opinion leader development programmes.

"I am delighted that Andy Mears has accepted the role of Chief Executive and I look forward to working closely with him to drive forwards the recently launched TrueVue platform from an improved financial footing," said Keen.

As of 1553 BST, Deltex Medical Group's shares were unchanged at 1.30p.

Related share prices
Deltex Medical Group (DEMG) share price